Related Articles
Combining selective inhibitors of nuclear export (SINEs) with chimeric antigen receptor (CAR) T cells for CD19‑positive malignancies
Bortezomib improves adoptive carbonic anhydrase IX‑specific chimeric antigen receptor‑modified NK92 cell therapy in mouse models of human renal cell carcinoma
A novel chimeric antigen receptor (CAR) system using an exogenous protease, in which activation of T cells is controlled by expression patterns of cell‑surface proteins on target cells
CD19/CD22 bispecific chimeric antigen receptor‑NK‑92 cells are developed and evaluated
Current status and future prospects of the strategy of combining CAR‑T with PD‑1 blockade for antitumor therapy (Review)